Table 6 FDA approved antibody-drug-conjugates (ADCs) [74]
From: How to select IgG subclasses in developing anti-tumor therapeutic antibodies
ADC drugs | Target | Indications | Antibody conjugation | Approval date |
|---|---|---|---|---|
Adcetris® (brentuximab vedotin) | CD30 | Relapsed HL and sALCL | Chimeric IgG1—cysteine | 2011 |
Kadcyla® (trastuzumab emtansine) | Her2 | Breast cancer | Humanized IgG1—lysine | 2013 |
Besponsa® (inotuzumab ozogamicin) | CD22 | r/r B-ALL | Humanized IgG4—lysine | 2017 |
Polivy® (polatuzumab vedotin) | CD79b | r/r DLBCL | Humanized IgG1—cysteine | 2019 |
Enhertu® (fam-trastuzumab deruxtecan-nxki) | Her2 | Breast cancer | Humanized IgG1—cysteine | 2019 |